Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study
Espitia-Hernandez et al., Biomedical Research, 31:5
Espitia-Hernandez et al., Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of.., Biomedical Research, 31:5
Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patients.
All treated patients were PCR- at day 10 while all control patients remained PCR+. The mean duration of symptoms was 3 days in the treatment group and 10 days in the control group.
|
recovery time, 70.0% lower, relative time 0.30, p < 0.001, treatment 28, control 7.
|
|
risk of viral+ at day 10, 97.2% lower, RR 0.03, p < 0.001, treatment 0 of 28 (0.0%), control 7 of 7 (100.0%), NNT 1.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), primary outcome.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Espitia-Hernandez et al., 15 Aug 2020, retrospective, Mexico, peer-reviewed, mean age 45.1, 5 authors, dosage 6mg days 1-2, 8-9, this trial uses multiple treatments in the treatment arm (combined with azithromycin and cholecalciferol) - results of individual treatments may vary.
